Presentation Information
[O16-01]Immunogenicity, Reactogenicity, and Safety of an mRNA-Based Seasonal Influenza and SARS-CoV-2 Multicomponent Vaccine, mRNA-1083, in Adults Aged ≥50 Years in Japan
*Osamu Kogawara1, Hiroyuki Fukase2, Alexander Rumyantsev3, Koichi Hashizume1, Seun Osibajo3, Lusine Kostanyan3 (1. Moderna Japan Co., Ltd., 2. General Incorporated Association, Clinical Research Hospital Tokyo, 3. Moderna, Inc.)